Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests
Executive Summary
Commissioner worries that fewer drugs may enter market in some categories because of drug development costs, and offers some post-market strategies for encouraging biosimilar development.
You may also be interested in...
Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers
Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.
Biosimilars Need Better Reimbursement, Not 'Kabuki' Coverage, Gottlieb Tells Insurers
Rebate arrangements that block biosimilar uptake under guise of lowering costs do patients no favors, US FDA Commissioner says at AHIP policy conference.
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
The FDA Commissioner called on payers to take steps to build the US biosimilar market and discouraged some early contracting schemes, calling them pay-for-delay tactics "dressed in the guise of rebates" in a notable speech at AHIP.